| Characteristic . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | Total (n = 249) . |
|---|---|---|---|
| Age, y | 44 (36–52) | 43 (37–49) | 43 (36–50) |
| Gender | |||
| Male | 107 (85) | 100 (81) | 207 (83) |
| Mode of transmission | |||
| Intravenous drug use | 19 (15.1) | 15 (12.2) | 34 (13.7) |
| Men who have sex with men | 65 (51.6) | 72 (58.5) | 137 (55) |
| Heterosexual | 34 (27) | 32 (26) | 66 (26.5) |
| Hepatitis C | 32 (25.4) | 28 (22.8) | 60 (24.1) |
| Baseline CD4 count (cells/µL) | 596 (433–810) | 568 (451–739) | 589 (443–762) |
| Nadir CD4 count (cells/µL) | 253 (122–367) | 240 (117–328) | 246 (120–327) |
| Weeks since undetectable viral load (<50 copies/mL) | 79.5 (38–157) | 113 (57–184) | 100 (45–166) |
| Previous nucleos(t)ide | |||
| Tenofovir | 93 (74) | 93 (76) | 186 (75) |
| Abacavir | 33 (26) | 30 (24) | 63 (25) |
| Characteristic . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | Total (n = 249) . |
|---|---|---|---|
| Age, y | 44 (36–52) | 43 (37–49) | 43 (36–50) |
| Gender | |||
| Male | 107 (85) | 100 (81) | 207 (83) |
| Mode of transmission | |||
| Intravenous drug use | 19 (15.1) | 15 (12.2) | 34 (13.7) |
| Men who have sex with men | 65 (51.6) | 72 (58.5) | 137 (55) |
| Heterosexual | 34 (27) | 32 (26) | 66 (26.5) |
| Hepatitis C | 32 (25.4) | 28 (22.8) | 60 (24.1) |
| Baseline CD4 count (cells/µL) | 596 (433–810) | 568 (451–739) | 589 (443–762) |
| Nadir CD4 count (cells/µL) | 253 (122–367) | 240 (117–328) | 246 (120–327) |
| Weeks since undetectable viral load (<50 copies/mL) | 79.5 (38–157) | 113 (57–184) | 100 (45–166) |
| Previous nucleos(t)ide | |||
| Tenofovir | 93 (74) | 93 (76) | 186 (75) |
| Abacavir | 33 (26) | 30 (24) | 63 (25) |
Dual therapy = switching to darunavir/r + lamivudine. Triple therapy = maintain triple therapy with darunavir/r + 2 nucleos(t)ide reverse transcriptase inhibitor. Data are expressed as median (interquartile range) or n (%).
| Characteristic . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | Total (n = 249) . |
|---|---|---|---|
| Age, y | 44 (36–52) | 43 (37–49) | 43 (36–50) |
| Gender | |||
| Male | 107 (85) | 100 (81) | 207 (83) |
| Mode of transmission | |||
| Intravenous drug use | 19 (15.1) | 15 (12.2) | 34 (13.7) |
| Men who have sex with men | 65 (51.6) | 72 (58.5) | 137 (55) |
| Heterosexual | 34 (27) | 32 (26) | 66 (26.5) |
| Hepatitis C | 32 (25.4) | 28 (22.8) | 60 (24.1) |
| Baseline CD4 count (cells/µL) | 596 (433–810) | 568 (451–739) | 589 (443–762) |
| Nadir CD4 count (cells/µL) | 253 (122–367) | 240 (117–328) | 246 (120–327) |
| Weeks since undetectable viral load (<50 copies/mL) | 79.5 (38–157) | 113 (57–184) | 100 (45–166) |
| Previous nucleos(t)ide | |||
| Tenofovir | 93 (74) | 93 (76) | 186 (75) |
| Abacavir | 33 (26) | 30 (24) | 63 (25) |
| Characteristic . | Dual Therapy (n = 126) . | Triple Therapy (n = 123) . | Total (n = 249) . |
|---|---|---|---|
| Age, y | 44 (36–52) | 43 (37–49) | 43 (36–50) |
| Gender | |||
| Male | 107 (85) | 100 (81) | 207 (83) |
| Mode of transmission | |||
| Intravenous drug use | 19 (15.1) | 15 (12.2) | 34 (13.7) |
| Men who have sex with men | 65 (51.6) | 72 (58.5) | 137 (55) |
| Heterosexual | 34 (27) | 32 (26) | 66 (26.5) |
| Hepatitis C | 32 (25.4) | 28 (22.8) | 60 (24.1) |
| Baseline CD4 count (cells/µL) | 596 (433–810) | 568 (451–739) | 589 (443–762) |
| Nadir CD4 count (cells/µL) | 253 (122–367) | 240 (117–328) | 246 (120–327) |
| Weeks since undetectable viral load (<50 copies/mL) | 79.5 (38–157) | 113 (57–184) | 100 (45–166) |
| Previous nucleos(t)ide | |||
| Tenofovir | 93 (74) | 93 (76) | 186 (75) |
| Abacavir | 33 (26) | 30 (24) | 63 (25) |
Dual therapy = switching to darunavir/r + lamivudine. Triple therapy = maintain triple therapy with darunavir/r + 2 nucleos(t)ide reverse transcriptase inhibitor. Data are expressed as median (interquartile range) or n (%).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
